| P/E (FY) | 16.3 | Sales (TTM) | SEK 11.29B |
| Earnings (TTM) | SEK 498.0M | ROE | 6.26% |
| Net Margin | 4.41% | ROIC | 9.20% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −12.38% | Sales Growth 3Y | 7.58% |
Arjo AB (publ) develops and sells medical devices and solutions aimed at improving clinical and financial outcomes in healthcare, with operations spanning Europe, Asia, Latin America, Africa, and the Pacific. Its offerings address patient handling, hygiene and disinfection, medical beds, pressure-injury and blood-clot prevention, diagnostics, leg-ulcer treatment, and obstetric and cardiac diagnostics, complemented by services such as dementia and bariatric care, prone positioning, early mobility, rehabilitation, equipment maintenance, and rental and financing. Its customers are private and public providers of acute and long-term care. The company was founded in 1957 and is headquartered in Malmo, Sweden.
| Market Cap | $746.1M | Trading Days | 2109 |
| 52W High | 36.36 |
| 52W Low | 23.64 |
| % Off High | −26.68% |
| YTD | −13.67% | 1Y | −21.16% |
| 3Y | −37.08% | 5Y | −70.06% |
| Since incept. (ann.) | 3.15% |
| Ann. Volatility (1Y) | 24.81% | Ann. Volatility (3Y) | 29.50% |
| Sharpe (1Y) | −0.86 | Sharpe (3Y) | −0.44 |
| Max Drawdown (1Y) | −30.69% | Max Drawdown (3Y) | −51.27% |
| Beta (3Y, vs SPY) | 0.46 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| MNPR | Monopar Therapeutics | $730.8M | — |
| AURA | Aura Biosciences, Inc. | $728.9M | — |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| CSTL | CASTLE BIOSCIENCES INC | $724.6M | — |
| XOMA | XOMA Royalty Corp | $722.3M | 27.5 |
| ANNX | Annexon, Inc. | $770.9M | — |
| GNFT.PA | SA GENFIT | $775.2M | 454.7 |
| RIGL | RIGEL PHARMACEUTICALS INC | $712.3M | 2.0 |
| SLDB | Solid Biosciences Inc. | $784.6M | — |
| CADL |
| Candel Therapeutics, Inc. |
| $709.3M |
| — |
